Cargando…
Development of anti-feline PD-1 antibody and its functional analysis
Antibodies against immune checkpoint molecules restore T-cell function by inhibiting the binding of PD-1 and PD-L1 and have been shown to exert therapeutic effects in various human cancers. However, to date, no monoclonal antibody that recognizes feline PD-1 or PD-L1 has been reported, and there are...
Autores principales: | Nishibori, Shoma, Kaneko, Mika K., Nakagawa, Takayuki, Nishigaki, Kazuo, Kato, Yukinari, Igase, Masaya, Mizuno, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126011/ https://www.ncbi.nlm.nih.gov/pubmed/37095139 http://dx.doi.org/10.1038/s41598-023-31543-6 |
Ejemplares similares
-
Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1)
monoclonal antibody, clone 28-8 against feline PD-L1
por: NISHIBORI, Shoma, et al.
Publicado: (2023) -
Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
por: Mizuno, Takuya, et al.
Publicado: (2020) -
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023) -
Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B)
monoclonal antibodies
por: IGASE, Masaya, et al.
Publicado: (2020) -
Expression of podoplanin in various types of feline tumor tissues
por: KAMOTO, Satoshi, et al.
Publicado: (2021)